Resources covering pharmaceutical aspects of the vaccination programme specific to COVID-19 Vaccine Pfizer-BioNTech

Comirnaty Children's Vaccine · Understanding differences and risks following its introduction

Our Pfizer-BioNTech standard operating procedures are now organised by both vaccination site location and vaccine type, to help with the introduction of Comirnaty (10 micrograms/dose) concentrate for Children 5 to 11 years. Read our article for a summary of the differences and risks to manage.

Answers to Questions specific to Pfizer-BioNTech vaccine

Answers to Medicines Optimisation questions related specifically to Pfizer-BioNTech vaccine

Pfizer-BioNTech: Handling in Trusts and Vaccination Centres

Pharmaceutical processes for Comirnaty concentrate for both adults and adolescents, and for children from initial ordering through to administration.

Pfizer-BioNTech: Handling in PCNs

Pharmaceutical processes for Comirnaty concentrate for both adults and adolescents, and for children from initial ordering through to administration.

Pfizer-BioNTech: Handling for Adult and Adolescent Vaccination

Pharmaceutical processes for Comirnaty (30 micrograms/dose) for Adults and Adolescents, from initial ordering through to administration for PCNs and Trusts.

Pfizer-BioNTech: Handling for Children’s Vaccination

Pharmaceutical processes for Comirnaty (10 micrograms/dose) for Children 5 to 11 years, from initial ordering through to administration for PCNs and Trusts.